Novartis receives FDA approval for Kisqali Femara Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open
“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.”

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.

April 24, 2026

By Claire Marie Porter and Paul Goldberg

NCI

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Tucked in at the end of a 20-minute talk that covered paylines, promising young investigators, and precision medicine, NCI Director Anthony G. Letai beefed up the alliteration with two more words that begin with a “p”: prevention and pilot.

April 24, 2026

By Sara Willa Ernst

Podcast

No need for a speculum? A new era of HPV screening

FDA has cleared the first at-home self-collection kit for HPV screening, removing significant obstacles to cervical cancer detection.

April 22, 2026

Health Equity Regulatory News

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Boca Raton resident Gabriela Sanchez recently found herself stepping into a mobile outreach vehicle operated by Sylvester Comprehensive Cancer Center.

April 17, 2026

Vol.52 No.15

By Claire Marie Porter

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

April 17, 2026

Vol.52 No.15

By Jacquelyn Cobb

Cancer History Project Editorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

April 17, 2026

Vol.52 No.15

By Paul Goldberg

Novartis receives FDA approval for Kisqali Femara Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

YOU MAY BE INTERESTED IN

The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open
“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.”

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

No need for a speculum? A new era of HPV screening

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

Renew today!

Subscriber content

Never miss an issue!

Login

Novartis receives FDA approval for Kisqali Femara Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

YOU MAY BE INTERESTED IN

The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.”

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylinesThere’s “clear evidence that funding is moving and the system is working.”

No need for a speculum? A new era of HPV screening

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0

Never miss an issue!

Login

The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open
“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.”

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0